Adlai Nortye Business Summary

Adlai Nortye Ltd. (ANL) is a global clinical-stage biotechnology company that generates revenue primarily through strategic licensing agreements and capital market transactions, as it has not yet commercialized its oncology pipeline. The company operates through two primary business segments: RAS-targeted therapies, headlined by its pan-RAS(ON) inhibitor AN9025, and next-generation cancer immunotherapies, including oral PD-L1 inhibitors and multifunctional fusion proteins. In early 2026, the firm significantly bolstered its liquidity through a $140 million private placement and a $230 million licensing deal with ASK Pharm for Greater China rights to AN9025. ANL competes directly with other precision oncology and immunotherapy firms such as Monte Rosa Therapeutics, Nurix Therapeutics, Rapport Therapeutics, and Immunocore, positioning itself as a high-potential small-cap innovator with a specialized focus on overcoming RAS-mutant solid tumor resistance. Adlai Nortye was founded in 2016 by Chairman and CEO Yang (Carsten) Lu, a pharmaceutical veteran with over 20 years of experience who previously held leadership roles at Hybio Pharmaceutical. The executive team includes President Kaiyang (Tom) Tang and Head of Research & Development Archie Tse, MD, PhD, who joined in 2024 with a pedigree from CStone Pharmaceuticals, Merck, and Daiichi-Sankyo. The company’s board features notable industry figures such as Lars E. Birgerson, MD, PhD, a former executive at Roche and Genentech, and Roger Sawhney, MD, the current CFO of LB Pharmaceuticals and a former Director at KKR. ANL is backed by a high-profile investor base including Cormorant Asset Management, Columbia Threadneedle Investments, Point72, Balyasny Asset Management, and Casdin Capital.